High-dose chemotherapy without stem cell transplantation for refractory childhood systemic lupus erythematosus

Chemotherapy

Volumn 54, Issue 5, 2008, Pages 331-335

  Luo, Xue Qun ^a   Mo, Ying ^a   Ke, Zhi Yong ^a   Xu, Ling ^a   Jiang, Xiao Yun ^a   Zhang, Ting Ting ^a   Chen, Shu Mei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Intensive chemotherapy; Stem cell transplantation; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; LYMPHOCYTE ANTIBODY; PREDNISONE;

ADOLESCENT; ARTICLE; CASE REPORT; CHILDHOOD DISEASE; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; HEMOLYTIC ANEMIA; HUMAN; MALE; NEPHRITIS; NEUTROPHIL COUNT; PRIORITY JOURNAL; SCHOOL CHILD; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; STEM CELL TRANSPLANTATION;

EID: 49549102195     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151539     Document Type: Article

References (25)

1. Leman TJA, Onel K: Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000;136:243-247.
2. Lee BS, Cho HY, Kim EJ, Kang HG, Ha IS, Cheong HI, Kim JG, Lee HS, Choi Y: Clinical outcome of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 2007;22:222-231.
3. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, Deschenes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B: Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:571-573.
4. Marks SD, Patey S, Brogan PA, Hasson N, Pikington C, Woo P, Tuilus K: B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52:3168-3174.
5. Edelbauer M, Jungraithmary T, Zimmerhackl LB: Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol 2005;20:811-813.
6. Lehman TJ: Current concepts in immunosuppressive drug therapy of systemic lupus erythematosus. J Rheumatol Suppl 1992;33:20-22.
7. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, Verda L, Krosnjar N, Quigley K, Yaung K, Villa Bs M, Takahashi M, Jovanovic B, Oyama Y: Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006;295:527-535.
8. Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulffraat N, Besalduch J, Bingham SJ, Emery P, Brune M, Fassas A, Faulkner L, Ferster A, Fiehn C, Fouillard L, Geromin A, Greinix H, Rabusin M, Saccardi R, Schneider P, Zintl F, Gratwohl A, Tyndall A: Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004;13:168-176.
9. Brodsky RA, Smith BD: Bone marrow transplantation for autoimmune diseases. Curr Opin Oncol 1999;11:83-86.
10. Cohen Y, Nagler A: Treatment of refractory autoimmune disease with ablative immunotherapy. Autoimmun Rev 2004;3:21-29.
11. Petri M, Jones RJ, Brodsky RA: High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-173.
12. Gladstone DE, Presturd AA, Pradhan A, Styler MJ, Topolsky DL, Crilley PA, Hoch S, Huppert A, Brodsky I: High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 2002;11:405-410.
13. Petri M, Hellmann D, Hochberg M: Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53-59.
14. Jones RJ, Barber JP, Vala MS, et al: Assessment of aldehyde dehydrogenase in viable cells. Blood 1995;85:2742-2746.
15. Brodsky RA, Sensenbrenner LL, Smith BD, Dorr D, Seaman PJ, Lee SM, Karp JE, Brodsky I, Jones RJ: Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001;135:477-483.
16. Drachman DB, Brodsky RA: High-dose therapy for autoimmune neurologic diseases. Curr Opin Oncol 2005;17:83-88.
17. Drachman DB, Jones RJ, Brodsky RA: Treatment of refractory myasthenia: 'rebooting' with high-dose cyclophosphamide. Ann Neurol 2003;53:7-9.
18. Cohen Y, Polliack A, Nagler A: Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Des 2003;9:279-288.
19. Ruiz-Irastorza G, Khamashta MA, Hughes GR: Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs 2000;9:1581-1593.
20. Jones OY, Alexander PJ, Lacson A, Gok F, Feliz A, Marikar Y, Madivi C, Jones JM, Good RA: Effects of fludarabine treatment on murine lupus nephritis. Lupus 2004;13:912-916.
21. Viallard JF, Mercie P, Faure I, Pellegrin JL, Leng B: Successful treatment of lupus with fludarabine. Lupus 1999;8:767-769.
22. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, Holland SM, Linton GF, Miller JA, Leitman SF, Read EJ, Malech HL: Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopietic allograft. N Engl J Med 2001;344:881-888.
23. Samonis G, Kontoyiannis D: Infectious complications of purine analog therapy. Curr Opin Infect Dis 2001;14:409-413.
24. Dogan AL, Dogan A, Canpinar H, Duzguncinar O, Demirpence E: Effect of fludarabine on leukocyte functions. Chemotherapy 2004;50:283.
25. Dearden C, Walde R, Else M, Richards S, Milligan D, Hamblin T, Catovsky D: The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:1820-1826.